INTERNATIONAL GRANTS

NO.

NAME

TYPE

TITLE

SPONSOR

1

DR. TENGKU AHMAD DAMITRI AL-ASTANI ENGKU DAUD @ TENGKU DIN

USM’S DATA ENRICHMENT AND COMMERCIALIZATION-APPLICATION OF ARTIFICAL INTELLIGENCE OF DEEP LEARNING ON BREAST CANCER DETECTION

ILMM PTE LTD

2

DR. ZETI NORFIDIYATI SALMUNA @ AYUB

INVESTIGATOR DRIVEN RANDOMIZED CONTROLLED TRIAL OF CEFIDOROCOL VERSUS STANDARD THERAPY FOR HEALTHCARE ASSOCIATED AND HOSPITAL ACQUIRED GRAM-NEGATIVE BLOOD STREAM

THE UNIVERSITY OF QUEENSLAND

NO.

NAME

TYPE

TITLE

SPONSOR

1

DR. SHAFINI MOHAMED YUSOFF

PRIVATE

ROLE OF HAEMOCYTOMETRIC PARAMETERS IN PREDICTING SEVERITY OF COVID-19 INFECTIONS

SYSMEX ASIA PASIFIC PTE LTD

2

PROF. MADYA DR. MOHD ZULFAKAR MAZLAN

PRIVATE

EVALUATION OF AGREEMENT BETWEEN POINT-OF-CARE AND LABORATORY AUTOMATED IMMUNOASSAY IN PROCALCITONIN AND C REACTIVE PROTEIN MEASUREMENT AMONG CRITICALLY ILL PATIENTS

GUANGZHOU WONDFO BIOTECH CO. LTD

3

 PROF. MADYA DR. MAYA MAZUWIN YAHYA

PRIVATE

GLOBAL SURGERY (WORKSTREAM 2) IMPACT OF COVID-19 ON BREAST CANCER SURGERIES

INTERNATIONAL COLLABORATION OFFICE, SIGNHEALTH DUKENUS GLOBAL HEALTH INSTITUTE (SDGHI), SINGAPORE

4

DR. MOHD FAIZAL MOHD ZULKIFLY

PRIVATE

DETERMINING THE ANTIDEPRESSANT EFFECTS AND NEURAL NETWORK CHANGES INDUCED BY INTERNITTENT THETA-BURST STIMULATION (ITBS) IN MAJOR DEPRESSIVE DISORDER (MDD) PATIENTS

INTERNATIONAL BRAIN RESEARCH ORGANIZATION (IBRO)

5

DR. MOHD HAFIZUDDIN HUSIN @ MOHD HUSSIN

PRIVATE

CORRELATION BETWEEN LIVER STIFFNESS MEASURED BY TWO-DIMENSIONAL SHEAR WAVE ELASTOGRAPHY AND PROTHROMBIN INDUCED VITAMIN K ABSENCE II (PIVKA-II) IN HEPATOCELLULAR CARCINOMA PATIENTS RECEIVING LOGO-REGIONAL THERAPY IN USM

EAST COAST SOCIETY OF NEURORADIOLOGY AND INTERVENTIONAL RADIOLOGY (ECSNIR)

6

PROF. MADYA DR. MOHD ZULFAKAR MAZLAN

PRIVATE

A CLINICALLY-ORIENTED ANTIMICROBIAL RESISTANCE SURVEILLANCE NETWORK FOR HEALTHCARE-ASSOCIATED INFECTIONS (ACORN-HAI)

NATIONAL UNIVERSITY OF SINGAPORE (NUS)

7

PROF. MADYA DR. ZAHARAH SULAIMAN

PRIVATE

PROJEK IBU SUSU KELANTAN

ARBA INTERNATIONAL WAQF (L) FOUNDATION

8

DR. ZEFARINA ZULKAFLI

PRIVATE

THE ROLE OF ADVANCED RED BLOOD CELL PARAMETERS FOR DETECTION OF ALPHA THALASSAEMIA TRAIT AMONG REGULAR WHOLE BLOOD DONORS

SYSMEX ASIA PACIFIC PTE LTD, SINGAPORE

No.

Name

Type

Title

Sponsor

1

DR. NORZILA BINTI ZAKARIA

Private

PROBIOTICS FOR BRAIN HEALTH BENEFITS

PROBIONIC CORP

2

DR. MOHD HANIFAH BIN JUSOH

Private

PROBIOTICS FOR ORTHOPEDIC BENEFITS

PROBIONIC CORP

3

DR. NUR SUHAILA BINTI IDRIS

Private

PROMOTION OF SMOKE-FREE AND COVIC-19 PREVENTION IN THE STATE OF KELANTAN - "PROTECT YOUR LUNGS: NO SMOKING, FREE COVIC-19"

SOUTH EAST ASIA TOBACCO CONTROL ALLIANCE (SEATCO)

4

ASSOC. PROF. DR. MOHD ZULFAKAR BIN MAZLAN

Private

MULTIPLE PARALLEL MULTI-CENTRE, RANDOMISED, SINGLE BLINDED CLINICAL TRIALS COMPARING CONSERVATIVE VS. LIBERAL OXYGENATION TARGETS IN MECHANICALLY VENTILATED ADULTS IN THE INTENSIVE CARE UNIT

MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND (MRINZ)

5

DR. MOHAMAD IKRAM BIN ILIAS

Private

EVALUATING THE BURDEN OF PAEDIATRIC PNEUMOCOCCAL PNEUMONIA IN MALAYSIA PRIOR TO AND DURING PNEUMOCOCCAL CONJUGATE VACCINE (PCV) IMPLEMENTATION

MERCK CHARPE AND DOHME (MSD)

6

ASSOC. PROF. DR. MUHAMAD SAIFUL BAHRI BIN YUSOFF

Private

CALOHEA: MEASURING AND COMPARING ACHIEVEMENTS OF LEARNING OUTCOMES IN HIGHER EDUCATION IN ASIA - MEDICINE

ERASMUS+

7

ASSOC. PROF. DR. ZAHARAH SULAIMAN

Private

QUALITATIVE ASSESSMENT ON SEXUAL AND REPRODUCTIVE HEALTH AND RIGHTS, AND HEALTH SERVICE ACCESS AMONG WOMEN LIVING WITH HIV IN MALAYSIA

THE JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (UNAIDS)

8

DR. CHANDRAN A/L NADARAJAN

Private

DEEP LEARNING ADVANCEMENT FOR IMAGE GUIDED CLASSIFICATION : APPLIED TO GYNECOLOGY

YILDIZ TECHNICAL UNIVERSITY, TURKEY

9

DR. ZEFARINA BINTI ZULKAFLI

Private

CLINICAL UTILITY OF MICRO-R AND HYPO-HE IN THE DIAGNOSIS OF LATENT IRON DEFICIENCY IN HOSPITAL UNIVERSITI SAINS MALAYSIA

SYSMEX ASIA PACIFIC PTE LTD, SINGAPORE

10

ASSOC. PROF. DR. ROSNAH BINTI BAHAR

Private

CLINICAL UTILITY OF MICRO-R AND HYPO-HE IN THE DIAGNOSIS OF THALASSEMIA TRAIT IN HOSPITAL UNIVERSITI SAINS MALAYSIA

SYSMEX ASIA PACIFIC PTE LTD, SINGAPORE

11

DR ZETI NORFIDIYATI BT SALMUNA

Clinical Research

PROT NO: GAME CHANGER - "Investigator Driven Randomized Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare Associated and Hospital Acquired Gram-negative Blood Stream Infection"

The University of Queensland

12

ASSOC PROF DR AZLAN BIN HUSIN

Clinical Research

PROT NO: MOR208C310 - "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP versus R-CHOP in Previously Untreated, High-Intermediate and High-risk Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)"

MorphoSys AG

NO

NAME

TYPE

TITTLE

SPONSOR

1

Profesor Madya Dr. Sarina Sulong

Agensi Luar

Discovery Of Microsatellite Instability Status In Colorectal Carcinoma Patients In Hospital USM : Potential Impact Of Molecular Pathology In Patient Management

Newcastle University Medicine Malaysia (NUMED)

2

Dr. Tengku Ahmad Damitri Al-Astani Tengku Din

Agensi Luar

Assessment Of Familial Cancers Samples Collection In Hospital USM Towards The Molecular Analysis

Newcastle University Medicine Malaysia (NUMED)

3

Profesor Dr. Rosline Bt Hassan

Agensi Luar

Familial Cancers In Hospital USM : Future Direction Of Internal Database Development For Biobanking

Newcastle University Medicine Malaysia (NUMED)

4

Rohimah Mohamud, Imunologi (Dr)

Agensi Luar

Ultra-Sensitive Compact Immunoassay System "Express Biohecker" Using Fluorescent Janus Particles For Rapid Sars-Cov-2 Detection

AUN / SEED - NET

NO.

NAME

TYPE

TITLE

SPONSOR

1

PROF. MADYA DR. MOHD ZULFAKAR MAZLAN

PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF CONTINUOUS BETALACTAM ANTIBIOTIC INFUSION COMPARED TO INTERMITTENT BETA-LACTAM ANTIBIOTIC INFUSION IN CRITICALLY ILL PATIENTS: A SUBSTUDY OF THE BLING III

THE GEORGE INSTITUTE FOR GLOBAL HEALTH, AUSTRALIA

NO

NAME

TYPE

TITTLE

SPONSOR

1

Profesor Madya Dr. Zaharah Sulaiman

Agensi Luar

Expression Of Breast Milk : Challenges And Experience Of Malaysian Women

World Alliance For Breastfeeding Action Berhad

NO

NAME

TYPE

TITTLE

SPONSOR

1

Profesor Dr. Lee Yeong Yeh

Agensi Luar

Morinaga-USM Gut Health & Microbiota Project: Role Of Bifidobacterium Infantis M63 In Restoring Gut Microbiota Balance Of Irritable Bowel Syndrome (Project 1) And Type-2 Diabetes Mellitus (Project 2)

Morinaga Milk Industry Co. Ltd

2

Profesor Madya Dr. Mohd Pazudin Bin Ismail

Agensi Luar

Malaysia Glycaemia In Pregnancy Cohort (Magic) Study

Newton-Ungku Omar Fund

3

Profesor Madya Dr. Rohana Binti Abd. Jalil

Agensi Luar

Analysis Of Sugar Composition In Malaysia: Contribution Toward The Harmonisation Of The Database For Asian Nutrition And Food Culture Research Center, Japan

The Sumitomo Foundation

NO

NAME

TYPE

TITTLE

SPONSOR

1

Profesor Dr. Zilfalil Bin Alwi

Agensi Luar

Geran Penyelidikan Muhammed Ariff (MAS) : Mitochondrian DNA (Mtdna) Profiling Of Nusantara And Cape Malays And Its Relationship With Historical, Cultural And Migration Pattern Of The Malay Population

Nanyang Technological University (NTU)

2

Profesor Madya Dr. Muzaimi Mustapha

Agensi Luar

Intellirehab - Intelligent Medical System With Customised Exercises For Personalized Home Telerehabilitation

Newton Ungku Omar Fund (Malaysian Industry-Government Group For High Technology (MIGHT))

NO

NAME

TYPE

TITLE

SPONSOR

1

Dr. Imran Ahmad, Perubatan Keluarga

Geran Luar

A Comparative Study Of Drug Addiction Rehabilitation Between Japan and Malaysia: Feasibility Of Setting Up Similar Centers in Malaysia

The Sumitomo Foundation

NO

NAME

TYPE

TITLE

SPONSOR

1

PM Dr. Rohana Abdul Jalil, Perubatan Masyarakat

Geran Luar

School Lunch Program 'Kyushoku' : What Malaysian Can Learn From Japan

Sumitomo Foundation, Japan

NO

NAME

TYPE

TITLE

SPONSOR

1

Dr. Wan Mohd Izani Wan Mohamad, Perubatan

Kajian Klinikal

A Phase 3, Ranomized, Double-Blind, Placebo-Controlled, Parellel Group Study To Evaluate The Efficacy and Safety of Ranolazine When Added To Glimepiride in Subjects With Type 2 Diabetes Mellitus

Gilead Sciences, Inc

2

Dr. V. M. K Bhavaraju, Perubatan Nuklear

Kajian Klinikal

Study Of A Randomized Double-Blind, Placebo-Controlled Study To Evaluate The Long Term Safety And Efficacy of Darbepoetin Alfa Administered at 500mg Once-Every-3 Weeks in The Anemic Subjects With Advanced Stage Non-Small Cell lung Cancer Receiving multi-Cycle Chemotherapy

International (Hong Kong)

3

PM Dr Biswa Mohan Biswal, Perubatan Nuklear

Kajian Klinikal

Pivotal Study In Breast Cancer Patients Investigatoring Efficacy and Safety of LA-EP2006 and Neulasta R

International (UK)

4

Dr. Nor Aizal Che Hamzah, Perubatan

Kajian Klinikal

A Phase III, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/ Ribavirin In Chronic HCV Genotype Iil28b cc Subjects (protocol No:P07755) (Also Known MK3034-040-01) MK3034-040 Site No.344 (the Protocol)

MERCK SHARP & DOHME (I.A) CORP

5

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

Study The Safety And/Or Efficacy of MK0431 Sitagliptin (The Study Drug) / Study of MK0431 in Pediatrik Patients With Tyoe 2 Diabetes

MERCK SHARP & DOHME (I.A) CORP

6

PM Dr. Kamarul Aryffin Baharuddin, Perubatan Kecemasan

Geran Luar

A Comprehensive Study on Home Care Nursing Between Japan and Malaysia

SUMITOMO FOUNDATION

NO

NAME

TYPE

TITLE

SPONSOR

1

PM Dr Biswa Mohan Biswal, Perubatan Nuklear

Kajian Klinikal

A Phase 3, randomized, double-Blinded Study of IMC-1121B and besr Supportive cars (BSC) versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum-or Fluoropyrimidine-Containing Combination Therapy

Quintiles

2

PM Dr. Muzaimi Mustapha, Neurosains

Geran Luar

CB1 Cannabinoid Receptor As Cerebellar Molecular Targets Of Mitragyna Speciosa (Ketum) Addiction In The Brain Of Mitragynine-Sensitised Albino Wistar Rats

COMSTECH-TWAS

3

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A 24 Week, Randomized, Double-Blind, Active-Controlled, Parallel Group Trial To Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotheraphy in Newly Diagnosed, Treatmentnaive, Uncontrolled Type 2 Diabetes Mellitus Patients

ICON Clinical Research limited (Ireland)

4

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group, 18-Week Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin Compare With Placebo Alone or in Combination With a Sulphonylurea

Johnson & Johnson Sdn Bhd

5

PM Dr. Rahimah Zakaria, Fisiologi

Geran Luar

The Combined Effects of Ovariectomy and Chronic Social Instability Stress on Cognitive Functions, Depressive Behaviour and Biochemical Changes in female Rates Treated with Tualang Honey

Ministry Health of Oman

6

Prof Dr Van Rostenberghe Hans Luc Aster, Pediatrik

Geran Luar

SEA-URCHIN: South East Asia - Using Research For Change In Hospital - Acquire Infection in Neonates

Monash University, Victoria

7

Dr. Azlan Husin, Perubatan

Kajian Klinikal

A Randomized, Controlled, Double- Blind Phase III Trial To Compare The Efficacy, Safety and Pharmacokinetics of GP2013 Plus CVP vs. MabThera(R) Maintenance Therapy in Patients With Previously Untreated,Advanced Stage Follicular Lymphoma

PPD Development (S) Pte Ltd

NO

NAME

TYPE

TITLE

SPONSOR

1

Dr. V. M. K Bhavaraju, Perubatan Nuklear

Kajian Klinikal

A Randomized, double Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)

Amgen (Asia) Limited

2

Prof Dr Nik Mohamed Zaki Nik Mahmood, O&G

Kajian Klinikal

A Phase 3, Randomized, Double-Blind Trial Of Weekly Paclitaxel Plus AMG 386 or Placebo In Women With recurrent Partially Platinum Sensitive Or resistant Epithelial Ovarian, Primary Peritoneal Or Fallopian Tube Cancers

AMGEN Inc.

3

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

1218.66: A Randomized, Double Blind, Placebo-Blind, Placebo-Controlled parallel group Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug Naive or previously Treated (6 Weeks Washout) Type 2 Diabetic Patients With Insufficient Glycaemic Control

Boehringer Ingelheim

4

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

1218.65: A Randomised, Double-Blind, Placebo-Controlled Parallel Group efficacy and Safety Study of Linagliptin (5 mg Administered orally once daily) Over 24 Weeks in type 2 Diabetic Patients with Insufficient Glycaemic Control Despite Metformin Therapy

Boehringer Ingelheim

5

Prof Dr. Suzina Sh. Ab. Hamid, Unit Bank Tisu

Geran Luar

Studies On Functional Properties Of Processed and Irradiated Human Amniotic Membranes

IAEA

6

PM Dr Biswa Mohan Biswal, Perubatan Nuklear

Kajian Klinikal

A Phase 3, Randomized, Double Blind Study Of IMC-1121B And Best Supportive Care (BSC) Versus Placebo And BSC In The Treatment Of Metastatic Gastric Or Gastroesophageal Junction Adenocarcinoma Following Disease Progression On First-Line Platinum- Or Fluoropyrimidine- Containing Combination Therapy

ImClone LLC

7

Dr. Mohd Azhar Mohd Yasin, Psikiatri

Kajian Klinikal

Safety, Tolerability and Treatment Response Of Paliperidone Palmitate In Subjects With Schizophrenia When Switching From Oral Antipsychotics

Jenssen-Cilag (Johnson & Johnson Sdn Bhd)

8

Prof Dr Jafri Malin Abdullah, Neurosains

Geran Luar

Surgical Trial In Lobar Intracranial Haemorrhage, STICH II

NEWCASTLE UPON TYNE HOSPITALS NHS TRUST

9

Prof Dr Wan Mohamad Wan Bebakar, Perubatan

Kajian Klinikal

NN1250-3586
BEGINTM: Once Asia A PAn Asian Trial Comparing Efficacy And Safety Of Insulin NN1250 And Insulin Glargine As Add-On To OAD(s) In Subjects With Type 2 Diabetes, A 26-Week Randomised, Confirmatory, Controlled, Open Label, Multicentre, Multinational Treat-To-Target Trial Comparing The Efficacy and Safety SIBAAnd Insulin Glargine, Both Injected Once Daily As Add On To Current OAD Treatment In Insulin Naive Subjects With Type 2 Diabetes mellitus Qualifying For More Intensified Treatment, Trial Phase: 3a

Novo Nordisk

10

Prof Dr Wan Mohamad Wan Bebakar, Perubatan

Kajian Klinikal

NN5401-3597
BOOSTTM: Intensify All, A Pan Asian Trial ComparingEfficacy And Safety Of NN5401 And Biphasic Aspart 30 in Type 2 Diabetes, A 26-Week Trial, Randomised, Open-Label, Two-Arm, Parallel Group, Treat-To-Target Study Comparing Efficacy and Safety Of The Soluble Insulin Analogue Combination (SIAC) Twice Daily With Biphasic Insulin Aspart 30 Twice Daily, With Or Without Metformin In Subjects With Type 2 Diabetes In Inadequate Glycemic Control On Once Or Twice Daily Insulin Regimen With Or Without Metformin, Trial Phase 3a

Novo Nordisk

11

Dr. Zarina Zainan Abidin, Psikiatri

Kajian Klinikal

A Randomized, double-Blind, Placebo-Controlled, Parallel-Group Study Of Paliperidone Palmitate Evaluating Time To Relapse in Subjects with Schizoaffective Disorder

Ortho-McNeil Janssen Scientific Affairs

12

PM Dr. Kirnpal Kaur Banga Singh, Mikrobiologi

Geran Luar

To Provide Malaysia Bacterial Isolates For The Sentry Antimicrobial Surveillance Program in 2010

Sentry Antimicrobial Surveillance

NO

NAME

TYPE

TITLE

SPONSOR

1

Prof Dr Abdul Aziz Baba, Perubatan

Kajian Klinikal

FORTIS-M: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients with Non-Small Lung Cancer Who Have Failed Two or More Treatment Regimens.

Agennix Incorporated

2

Dr. V. M. K Bhavaraju, Perubatan Nuklear

Kajian Klinikal

A Randomized, Multicenter, Open-Label, Phase 3. Study To Compare The Efficacy and safety Of Panitumumab And Cetuximab In Subjects With Previously Treated, Wild-Type KRAS, Metastatic Colorectal Cancer

Amgen (Asia) Ltd

3

Prof Dr. Baharudin Abdullah, ORL

Kajian Klinikal

A Phase II, Randomized Controlled Trial of Foscan¨ - Mediated Photodynamic Therapy Versus Brachytherapy in Patients with Recurrent or Persistent Nasopharngeal Carcinoma

Clinical Research Centre

4

Prof Dr Wan Mohamad Wan Bebakar, Perubatan

Kajian Klinikal

A Randomised, Double Blind, Placebo-Controlled, 3 Parallel Group Efficacy And safety Study Of Linagliptin 2.5 mg Twice Daily Versus 5mg Once Daily Over 12 Weeks As Add-On Therapy To A Twice Daily Dosing Regimen Of Metformin In Patients With Type 2 Diabetes Mellitus And Insufficient Glycaemic Control

Boehringer Ingelheim

5

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide when Used in Combination with Metformin in Subjects with Type 2 Diabetes.

Brit Insurance Limited

6

PM Dr Zurkurnai Yusof, Perubatan

Kajian Klinikal

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group,  Multicenter, Multi-National Study For Evaluation of Efficacy and Safety of DU-176B versus warfarin in subjetcs with atrial fibrillation Ð Effective aNticoaGulation with Factor xA next Generation in Atrial Fibrillation (ENGAGE AF Ð TIMI 48).

Daiichi Sankyo Pharma Development

7

PM Dr Zurkurnai Yusof, Perubatan

Kajian Klinikal

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed Ð The TRILOGY ACS Study.

Eli Lilly & Co

8

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Multicenter, Randomized,Open Label, Active Controlled Study To Compare The efficacy, safety And Tolerability Of Taspoglutide (RO5073031) Versus Insulin Glargine In Insulin-Naive Type 2 Dabetic patients Inadequately Controlled With Metformin and Sulfonylurea Combination Therapy

F. Hoffmann - La Roche AG

9

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Assess The Effects Of Taspoglutide (RO5073031) On Cardiovascular Outcomes In Subjects With Inadequated Controlled Type 2 Diabetes And Established Cardiovascular Disease

F. Hoffmann - LA Roche Ltd

10

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

Cardiovascular Outcomes Study to Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With A Recent Acute Coronary yndrome (ACS) Event And Type 2 Diabetes Mellitus (T2D) (ALECARDIO Study)

F. Hoffmann-La Roche AG

11

PM Dr Biswa Mohan Biswal, Perubatan Nuklear

Kajian Klinikal

BreaST Cancer with Overexpression of ErbB2- Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM).

Glaxo Smith Kline

12

PM Dr Zurkurnai Yusof, Perubatan

Kajian Klinikal

Effects Of Ivabradine In Patient With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double Blind Placebo-Controlled International Multicenter Study

Institut de Researches Internationals Servier (I.R.I.S)

13

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Randomized, Doubl-Blind, Placebo-and Active- Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase.

Johnson & Johnson Pharmaceutical

14

PM Dr. Zakuan Zainy Deris, Mikrobiologi

Kajian Klinikal

Comparison Activity of Carbepenem Testing E Ð Test Extended Study.

Johnson & Johnson Sdn Bhd

15

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled, Study Of The Effects Of Canagliflozin (JNJ-28431754) On Cardiovascular Outcomes In Adult Subjects With Type 2 Diabetes Mellitus (CANVAS Trial)

Johnson & Johnson Sdn. Bhd

16

Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga

Kajian Klinikal

Hypoglycaemia in Sulphonylurea Treated Type 2 Diabetes Mellitus Subjects Undergoing Ramadhan Fasting.

Merck & Co Inc

17

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono-or Dual Combination Oral Antihyperglycemic Therapy.

Merck & Co Inc

18

Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga

Kajian Klinikal

A Phase Iia, Multicenter, Randomised, Placebo and Active Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK3577 in Patients with Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control

Merck Sharp & Dohme

19

PM Dr Zainal Darus, Perubatan

Kajian Klinikal

A Phase III, Multicenter, Double-Blind, Double-Dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 versus Simvastatin for the Treatment of Dyslipidaemia in Subjects with Chronic Kidney Disease on Dialysis (incorporating a Placebo-controlled Withdrawal Phase)

Mitsubishi Tanabe Pharma Corporation

20

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Cross Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Diabetic Patients in Asia & to Evaluate Perceptions and Practices of Physicians & Patients About Diabetes Management in Asia, Observational Study.

Novo Nordisk

21

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

The Effect of NovoMix¨ 30, Levemir or NovoRapid¨ (alone or in combination) in Subjects with Type 2 Diabetes Previously Treated with Other Anti-Diabetic Medication. A 24-Week,International, Prospective, Multi-Centre, Open-Labelled, Non-Interventional Study.

Novo Nordisk

22

Prof Dr Wan Mohamad Wan Bebakar, Perubatan

Kajian Klinikal

A 26 Week, Randomized, Open Labelled, Two Arm, Parallel Group, Treat-To -Target Trial Comparing Efficacy And Safety Of Double Insulin Analogue Combination (SIAC) Twice Daily (BID) With Biphasic Insulin Apart (BIASP) 30 BID, With Or Without Metformin,With Or Without DPP-4 Inhibitor, With Or Without Pioglitazone In Subjects With Type 2 Diabetes In Inadequate Glycemic Control On Once Or Twice Daily Premixed Or Self Mixed Insulin Regimen With oe Without OADs, trial Phase 3a

Novo Nordisk

23

Prof Dr Wan Mohamad Wan Bebakar, Perubatan

Kajian Klinikal

A 26 Week, Randomised, Controlled, Open-label, Multicentre, Multinational, Three-Arm, Treat-To-Target Trial Comparing Efficacy And Safety Of Three Different Dosing Regimens Of Either Soluble Insulin Basal Analogue (SIBA) Or Insulin Glargine With Or Without Combination With OAD Treatment, In Subjects With Type 2 Diabetes Mellitus, Trial Phase 3a

Novo Nordisk

24

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

An Open Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety of Dutogliptin / PHX 1149T in Subjects with Type 2 Diabetes Mellitus.

Phenomix Corporation

25

Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga

Kajian Klinikal

i-COMPARE (Investigation of Thiazide Diuretics Combination in Treatment of Moderate to Severe Primary Hypertension).

Sanofi Aventis

26

Prof Dr Wan Mohamad Wan Bebakar, Perubatan

Kajian Klinikal

A Randomized, Placebo-Controlled, 2 Arm Parallel-Group, Multicenter Study With A 24 Week Double Blind Treatment Period Assessing The Efficacy And Safety Of Lixisenatide In Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine And Metformin

Sanofi Aventis

27

PM Dr Zurkurnai Yusof, Perubatan

Kajian Klinikal

A multicenter, Randomized, Double Blind, Placebo-Controlled Study To Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin In Addition To Standard Of Care In Subjects With Type 2 Diabetes And Acute Coronary Syndrome.

Takeda Global Research & Development Center, Inc

NO

NAME

TYPE

TITLE

SPONSOR

1

Prof Dr Abdul Aziz Baba, Perubatan

Kajian Klinikal

A Randomized , Double-blind , Pilot Study Comparing the Safety and Efficacy of Betamarc Plus Chemotherapy to Chemotherapy Alone in the Prevention and Treatment of Cancer Anorexia and Anorexia and Cachexia Syndrome in Patients with Advanced Non-Small Cell Lung Cancer

Anaborex, Inc USA

2

Prof Dr. Amran Ahmed Shokri, Ortopedik

Kajian Klinikal

A Phase III Randomized, Double Blind, Parallel-Group Study of the Efficacy and Safety of Oral Dabigatran Etixilate (150 mg bid) compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic VenousThromboembolism Following Initial Treatment for At Least 5 days with a Parenteral Anticoagulant Approved for this Indication.

Boehringer Ingelheim

3

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A randomized, double-blind, placebo controlled parallel group efficacy and safety study of BI1356 (5mg administered orally once daily) over 24 weeks, in drug na•ve or previously treated (6 weeks washout) type 2 diabetic patients with insufficient glycaemic control

Boehringer Ingelheim

4

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A 78 Week, Open Label Extension To Trials Assessing the safety and Efficacy of BI 1356 (5mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.

Boehringer Ingelheim

5

PM Dr Zurkurnai Yusof, Perubatan

Kajian Klinikal

A phase 3 randomized, Double-blind, Parallel-group, Multi-center Study of the safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely III Medical Subjects During and Following Hospitalization

Bristol - Mayers Squibb

6

Prof Dr Abdul Aziz Baba, Perubatan

Kajian Klinikal

An International, Multi-centre Open- Label 2-arm Phase III Trial of Adjuvant Bevacizumab in Triple Negative Breast Cancer

F Hoftman - La Roche Ltd

7

Prof Dr Ahmad Sukari Halim, Unit Sains Rekonstruktif

Geran Luar

Engineered Skin Substitute Using Chitosan Porous Skin Regenerating Template

INTERNATIONAL ATOMIC ENERGY AGENCY (IAEA)

8

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Randomized, Double-Blind, Placebo-Controlled, Double Dummy, Parallel Group, Multicenter, Dose Ranging Study in Subjects with Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally-Administered SGLT2 Inhibitor JNJ-28431754 with Sitagliptin as a Reference Arm

Janssen Cilag

9

PM Dr Mohd Jamil Yaacob, Psikiatri

Kajian Klinikal

A Multi-Center, Retrospective, Comparative Study to Investigate Drug Utilization Patterns And Treatment Period Associated With Atypical Antipsychotics Treatment in Schizophrenia and Schizoaffective Disorders: Aripiprazole,Olanzapine,Quetiapine and Risperidone.

Jenssen - Cilag

10

PM Dr Mohd Jamil Yaacob, Psikiatri

Kajian Klinikal

Pharmacoepidemiologic International Longitudinal Antipsychotic Registery.

Jenssen- Cilag

11

Dr. Che' Wan Aminud-din Hashim, Perubatan

Kajian Klinikal

A randomised, 4-week, placcebo-controlled, double-blind, 6 arm parallel group, dose-finding clinical trial, to assess the efficacy, safety and pharmacokinetics of three different doses of formoterol (6, 12 &18 µg, aclidinium bromide 200µg monotherapy and formoterol 12 µg monotherapy all administered once daily by inhalation via Almirall inhaler in patients with stable moderate to severe Chronic Obstructive Pulmonary Disease.

Laboratories Almiral, S.A

12

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of  MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin

Merck & Co Inc

13

Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga

Kajian Klinikal

A 76-week, Worldwide, Multicenter, Double-blind, Randomised, Placebo-controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When added to ongoing Therapy  With a Statin in patients with Hypercholesterolaemia or mixed Hyperlipidaemia.

Merck & Co USA

14

PM Dr Zurkurnai Yusof, Perubatan

Kajian Klinikal

A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk and not Adequately Controlled with Atorvastatin 20 mg: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin (10mg/40mg) versus Doubling the Baseline Dose to Atorvastatin 40 mg

Merck & Co.

15

Prof Dr Wan Mohamad Wan Bebakar, Perubatan

Kajian Klinikal

A Worldwide, Multicenter, Double-Blind, Randomized, placebo-Controlled, Dose Ranging Study to Evaluate the efficacy, safety and Tolerability of MK-0736 When Added to Ongoing Therapy With Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients With Diabetes and Hypertension.

Merck & Co. Inc

16

PM Dr. Juwita Shaaban, Perubatan Keluarga

Kajian Klinikal

Observational study to evaluate safety and effectiveness of the free combination of and 80mg/160mg valsartanamlodipine 5mg/10mg in the treatment of hypertension.
Symbicort Maintenance and Reliever Therapy, Experience in Real Life Setting in Malaysia- ÔSmarterÕ Study.

Novartis

17

Prof Dato' Dr Mafauzy Mohamed, Perubatan

Kajian Klinikal

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotheraphy in Subjects With Type 2 Diabetes Mellitus

Phenomix Corporation San Diego, CA

18

Prof Dr Shaiful Bahari Ismail, Perubatan Keluarga

Kajian Klinikal

A randomized, double blind, placebo controlled study evaluating the glycaemic effect of rimonabant added to metformin in patients with type 2 diabetes insufficiently controlled with metformin monotherapy-TOCCATA

Sanofi Adventis

19

Prof Dr Abdul Aziz Baba, Perubatan

Kajian Klinikal

A Multicenter, Double Blind, Placebo Controlled, Randomized Study of TroVax ¨ vs. Placebo in the First Line Treatment of Patients with Metastatic Colorectal Cancer Receiving Standard of Care.

Sanofi Aventis

20

Prof Dr Wan Mohamad Wan Bebakar, Perubatan

Kajian Klinikal

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, 24-Week Study Followed by an  Extension Assessing The Efficacy and Safety of AVE0010 in two Titration Regimens on top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled with Metformin

Sanofi Aventis

21

Prof Dr. Mohd Suhaimi Ab. Wahab, Farmakologi

Kajian Klinikal

A Retrospective Study to Assess the Clinical Burden of Community-Acquired Pneumonia (CAP) and Invasive Pneumococcal Disease (IPD)

Wyeth Research Division Of Wyeth Pharmaceuticals inc. Philedelphia